Table 1. Baseline characteristics of HCC patients receiving TACE and TACE + sorafenib.
| Baseline characteristics | TACE + sorafenib | TACE | P-value |
|---|---|---|---|
| Gender | |||
| Male, n (%) | 88 (85.44) | 117 (87.97) | 0.5678 |
| Female, n (%) | 15 (14.56) | 16 (12.03) | |
| Age | |||
| Mean ± SD [median] | 53.88 ± 12.25 | 57.35 ± 11.88 | 0.0291 |
| Child-Pugh class | |||
| A, n (%) | 45 (43.69) | 127 (96.21) | < 0.0001 |
| B, n (%) | 53 (51.46) | 5 (3.79) | |
| C, n (%) | 5 (4.85) | 0 (0.00) | |
| AFP | |||
| < 200, n (%) | 55 (53.40) | 59 (45.04) | 0.2041 |
| > = 200, n (%) | 48 (46.60) | 72 (54.96) | |
| ECOG | |||
| 0, n (%) | 52 (50.48) | 75 (56.39) | 0.484 |
| 1, n (%) | 33 (32.03) | 58 (43.61) | |
| 2, n (%) | 18 (17.47) | 0 (0.00) | |
| BCLC stage | |||
| B, n (%) | 68 (66.02) | 85 (63.91) | 0.7364 |
| C, n (%) | 35 (33.98) | 48 (36.09) | |
| HbsAg | |||
| Negative, n (%) | 6 (5.83) | 10 (7.52) | 0.6078 |
| Positive, n (%) | 97 (94.17) | 123 (92.48) | |
| Iodine oil deposit | |||
| < 50%, n (%) | 30 (29.13) | 73 (54.89) | 0.0001 |
| > = 50%, n (%) | 73 (70.87) | 60 (45.11) | |
| Tumor size | |||
| < 7 cm, n (%) | 65(65.66) | 133(100.0) | 0.0000 |
| > = 7 cm, n (%) | 34(34.34) | 0 (0.00) | |
| No. of tumors | |||
| < 3, n (%) | 58 (58.59) | 77 (58.33) | 0.9693 |
| > = 3, n (%) | 41 (41.41) | 55 (41.67) | |
| TACE frequency | |||
| < 3, n (%) | 67 (65.69) | 92 (69.17) | 0.5712 |
| > = 3, n (%) | 35 (34.31) | 41 (30.83) |